Product Images Lacosamide

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 5 images provide visual information about the product associated with Lacosamide NDC 72266-242 by Fosun Pharma Usa, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Lacosamide-Structure - Lacosamide Structure

Lacosamide-Structure - Lacosamide Structure

Lacosamide Carton Label - lacosamide carton label

Lacosamide Carton Label - lacosamide carton label

This is a medication guide for Lacosamide Injection, USP, which is a 200 mg/20 mL solution for infusion. It is intended for intravenous use only and comes in 5 x 20 mL single-dose vials. The medication guide should be dispensed to each patient. The inactive ingredients are sodium chloride, hydrochloric acid, and water for injection. Dosage information can be found in the package insert. The medication should be stored at 20°C to 25°C (68°F to 77°F), and any unused portion should be discarded. The medication is distributed by Fosun Pharma USA Inc. and is made in India. The provided code number is TS/DRUGS/2/2015.*

Lacosamide Vial Label - lacosamide container label

Lacosamide Vial Label - lacosamide container label

This is a description of a medication called Lacosamide Injection, which is distributed by Fosun Pharma USA Inc in Princeton, NJ. It is made in India and is for intravenous use only. It comes in a single-dose vial and has a code number of TS/DRUGS/2/2015 and a GTIN of 00372266242013. The lot number is not available due to an unvarnished area on the label. The concentration is 10mg/mL and it comes in a 20mL vial.*

Lacosamide-Figure-1 - lacosamide figure 1

Lacosamide-Figure-1 - lacosamide figure 1

The text contains a figure showing the percent reduction in seizure frequency per 28 days during the maintenance phase by dose for three different studies. Study 2 had a 5% reduction in seizures, while Study 3 had a 21% reduction. The figure also includes data on placebo and Lacosamide, showing a statistically significant difference in seizure reduction compared to placebo for Lacosamide at doses of 200, 400, and 600. No other information is available.*

Lacosamide-Figure-2 - lacosamide figure 2

Lacosamide-Figure-2 - lacosamide figure 2

This is a description of a figure (Figure 2) that shows the proportion of patients (in percentage) sorted by responder rate for Lacosamide and placebo groups in studies 2, 3, and 4. The text includes a table with 10 columns representing the responder rate, the number of patients (in N), and the percentage of patients in each category. There are also some symbols and characters that may represent technical notations.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.